OpenCharities

This text was generated using OCR and may contain errors. Check the original PDF to see the document submitted to the regulator. This document is also available as Markdown.

← Dkms Foundation

2024-12-31-accounts

Docusign Envelope ID: 926B8634-A476-4A2C-A1F1-AD31A7DA79D8

UK Impact Report

Year ending 31 December 2024

Tasneem, DKMS volunteer (East Midlands) and valued DKMS supporter

Docusign Envelope ID: 926B8634-A476-4A2C-A1F1-AD31A7DA79D8

Our Vision

To delete blood cancer.

==> picture [34 x 38] intentionally omitted <==

Our Mission

To give as many blood cancer patients as possible a second chance at life.

==> picture [39 x 39] intentionally omitted <==

Our Purpose

To raise awareness of blood cancer and blood disorders, register and retain potential stem cell donors to provide a second chance at life, raise funds to match donor registration costs, provide access to transplantation for more blood cancer patients, and improve blood cancer therapies by our own research.

Contents

Contents
ManagingDirectors’ introduction 02
Surpassingdonor registration 03
Representation matters 05
From frontline to lifeline 07
Fromgrief togiving 09
Givingback through fundraising 11
DKMS UK support to India & Access to Transplantation 13
Trustee report 15
Statement of fnancial activities 27
Waysyou can support us 51

1

Docusign Envelope ID: 926B8634-A476-4A2C-A1F1-AD31A7DA79D8

Managing Directors’ introduction

We warmly welcome and thank you for your engagement with and support for DKMS UK. We look back on an eventful year 2024 and to review all that was achieved is truly humbling.

We supported many wonderful initiatives for and with our patients and supporters, registering more than 50,000 potential lifesavers . Our new e-registration application simplifies the process of registering as a stem cell donor while enhancing the data quality.

Our fundraising efforts focused on forging long-term, mutually beneficial partnerships and we tried something totally new: we launched the DKMS Lottery, which exceeded all our expectations. The Marketing and Communications team prioritised brand awareness, as we recognised that to be truly successful, the foundation from which we must grow is ensuring the people of the UK know who we are, what we stand for and what our life-saving mission is.

2024 was also a significant year for our medical departments: we expanded our staff to provide an even better and faster service to patients’ transplant centre teams and our donors in 2025. DKMS UK also achieved World Marrow Donor Association (WMDA) accreditation, demonstrating our commitment to upholding the highest standards.

Fair and equitable access to stem cell transplantation is a focus for DKMS globally. In the UK, minority ethnic representation stands at 16%. This is simply not good enough and we are focused on significantly increasing activities within underrepresented communities to sign up more donors in 2025 and beyond. In 2024, DKMS UK extended its influence beyond national borders, supporting our organisation’s work in India. Additionally, DKMS’ global Access to Transplantation Programme offers patients in low-income countries access to treatment for blood cancer, thalassaemia, and sickle cell disease, which you can read about in this report.

We achieved so much in 2024, and yet there is so much more to do in 2025 and beyond. We are confident that the foundations we have laid this past year will, with your help, enable us to support even more blood cancer patients through our collective essential work.

Hasnein Alidina

Peter McCleave

Docusign Envelope ID: 926B8634-A476-4A2C-A1F1-AD31A7DA79D8

01 Surpassing donor registration

==> picture [24 x 14] intentionally omitted <==

----- Start of picture text -----
02
----- End of picture text -----

==> picture [61 x 17] intentionally omitted <==

----- Start of picture text -----
Representation
matters
----- End of picture text -----

01 Surpassing donor registration

==> picture [24 x 13] intentionally omitted <==

----- Start of picture text -----
03
----- End of picture text -----

==> picture [57 x 18] intentionally omitted <==

----- Start of picture text -----
From frontline
to lifeline
----- End of picture text -----

04 From grief to giving

05 Giving back through fundraising

06 DKMS UK support

When Tracy, a 34-year-old mother of two, was diagnosed with acute myeloid leukaemia (AML), she had four rounds of chemotherapy. After her fourth round, she relapsed and was told that she needed more chemotherapy and a stem cell transplant, her only chance for complete remission.

Tracy’s community in Omagh, Northern Ireland rallied around her. Her family reached out to DKMS for help organising a stem cell donor registration drive.

“Tracy didn’t have a 100% donor match,” explains her sister Louise. “So, we decided to make a public appeal locally, partnering with DKMS to encourage people to join the stem cell donor register.”

Volunteers spread the word on social media, distributed materials to local businesses, PTAs, churches, and clubs, and shared the event via word of mouth in their tight-knit community. The registration event saw 600 registrations in the first four hours. So many came that a second drive was held. People queued around the block to join the stem cell register as potential donors, and DKMS flew in more swabs from England to make sure everyone could sign up.

This was DKMS UK’s biggest registration event in recent years, thanks to the engagement of Tracy’s community networks and the people of Omagh. Almost 1,500 people turned up to support Tracy and patients like her, 1,336 people made online kit requests and £7,000 was raised . Tracy’s family were so moved to see the huge turnout and overwhelmed by the strength of their community.

3

Docusign Envelope ID: 926B8634-A476-4A2C-A1F1-AD31A7DA79D8

“We were absolutely overwhelmed by the support!”

4

Docusign Envelope ID: 926B8634-A476-4A2C-A1F1-AD31A7DA79D8

==> picture [70 x 53] intentionally omitted <==

----- Start of picture text -----
01
Surpassing
donor registration
----- End of picture text -----

==> picture [63 x 55] intentionally omitted <==

----- Start of picture text -----
02
Representation
matters
----- End of picture text -----

03

02 Representation matters

The South Asian community is underrepresented on the stem cell donor register. This year, however, an unwavering commitment to encourage people to sign up – regardless of background or religion – was embodied by Tasneem, a Leicester-based mother, GP and dedicated advocate for stem cell donation.

==> picture [57 x 18] intentionally omitted <==

----- Start of picture text -----
From frontline
to lifeline
----- End of picture text -----

04

Tasneem, a member of the DKMS East Midlands volunteering hub, has very personal reasons for supporting the work of DKMS: her own son Yusuf, now 16, was diagnosed with acute leukaemia five years ago. She recalls:

==> picture [45 x 19] intentionally omitted <==

----- Start of picture text -----
From grief
to giving
----- End of picture text -----

==> picture [77 x 52] intentionally omitted <==

----- Start of picture text -----
05
Giving back
through fundraising
----- End of picture text -----

==> picture [43 x 52] intentionally omitted <==

----- Start of picture text -----
06
DKMS UK
support
----- End of picture text -----

“During the time my son was going through treatment, I sadly saw children with cancer who passed away after not being able to find a match. This seemed so unfair. Being of South Asian origin myself, I saw this as an opportunity to help.”

5

Docusign Envelope ID: 926B8634-A476-4A2C-A1F1-AD31A7DA79D8

As a Muslim woman from a South e Asian background, as well as a GP, Tasneem is a trusted voice from ‘ her community.

She works to increase sign-ups to the stem cell donor register by helping to break down taboos and misunderstandings about stem cell donation.

Tasneem ran several events last year, including a donor registration drive in Highcross Shopping Centre, signing up 188 potential stem cell donors . Tasneem was also instrumental in establishing a partnership between DKMS UK and Islamic Relief, a renowned charity working to improve lives across the Muslim community.

Tasneem’s achievements remind us all that change begins with a single step — with every new person registered bringing hope to those searching for a compatible stem cell donor match.

6

Docusign Envelope ID: 926B8634-A476-4A2C-A1F1-AD31A7DA79D8

==> picture [70 x 53] intentionally omitted <==

----- Start of picture text -----
01
Surpassing
donor registration
----- End of picture text -----

==> picture [62 x 51] intentionally omitted <==

----- Start of picture text -----
02
Representation
matters
----- End of picture text -----

==> picture [24 x 14] intentionally omitted <==

----- Start of picture text -----
03
----- End of picture text -----

==> picture [59 x 18] intentionally omitted <==

----- Start of picture text -----
From frontline
to lifeline
----- End of picture text -----

==> picture [25 x 14] intentionally omitted <==

----- Start of picture text -----
04
----- End of picture text -----

03 From frontline to lifeline

==> picture [45 x 19] intentionally omitted <==

----- Start of picture text -----
From grief
to giving
----- End of picture text -----

==> picture [77 x 52] intentionally omitted <==

----- Start of picture text -----
05
Giving back
through fundraising
----- End of picture text -----

==> picture [43 x 52] intentionally omitted <==

----- Start of picture text -----
06
DKMS UK
support
----- End of picture text -----

Paul Smith, 57, from Bexley, has dedicated his life to service. He’s a former firefighter who has donated blood 83 times and aims for 100. “I’ve always felt that donating is such an easy way to help others,” he says. Paul joined the stem cell register over 20 years ago and is an advocate for donor registration, particularly within Black and other UK ethnic minority communities.

In January 2024, Paul found out he was a match. Despite initial concerns about his age, he went ahead with the donation, supported by his daughter.

“DKMS were amazing at every stage, and post-donation when I was invited to join a special Facebook group for DKMS donors – I really valued that support being available,” he adds.

7

Docusign Envelope ID: 926B8634-A476-4A2C-A1F1-AD31A7DA79D8

Paul’s donation gave a young woman in the UK a second chance at life. “My children are very proud of me, and that often makes me get a bit teary when I think about it”.

Paul’s dedication goes beyond donating. During Blood Cancer Awareness Month in 2024, he teamed up with DKMS UK to speak at The Prince’s Trust Youth Voice Programme’s #Time2Inspire International Youth Day event. He connected with young people from the Black community, many of whom had never heard of stem cell donation. His powerful storytelling sparked curiosity and action. “It’s really important for people in our community,” one participant shared. “More awareness should be raised, and I’d like to learn more about it.”

Paul’s dedication continues to inspire and is a testament to the power of one person’s actions.

8

Docusign Envelope ID: 926B8634-A476-4A2C-A1F1-AD31A7DA79D8

==> picture [70 x 53] intentionally omitted <==

----- Start of picture text -----
01
Surpassing
donor registration
----- End of picture text -----

04 From grief to giving

==> picture [62 x 51] intentionally omitted <==

----- Start of picture text -----
02
Representation
matters
----- End of picture text -----

==> picture [56 x 51] intentionally omitted <==

----- Start of picture text -----
03
From frontline
to lifeline
----- End of picture text -----

==> picture [45 x 56] intentionally omitted <==

----- Start of picture text -----
04
From grief
to giving
----- End of picture text -----

05 Giving back through fundraising

==> picture [43 x 52] intentionally omitted <==

----- Start of picture text -----
06
DKMS UK
support
----- End of picture text -----

Cecilia was a journalism student when her mother was diagnosed with diffuse large B-cell lymphoma. For over a year, she was by her mum’s side through gruelling chemotherapy and treatments.

When doctors needed monocytes, Cecilia didn’t hesitate; she underwent cell collection to help give her mum more time. Despite their best efforts, Cecilia’s mum sadly passed away. But instead of letting grief define her, Cecilia transformed her pain into purpose.

For her final-year journalism project, Cecilia created Dear Cells, a documentary exploring cell therapy.

Through interviews with medical experts, charities including DKMS, and survivors, she set out to demystify stem cell donation and share its lifesaving potential.

~{ \

Cecilia also registered as a stem cell donor and became a DKMS volunteer. From Freshers Fairs to patient-led drives and fundraising days, she brings warmth, empathy, and a powerful personal story.

Now leading her university’s Stem Cell Society, a DKMS-affiliated volunteering group, Cecilia is committed to engaging students, staff, and local communities in

9

Docusign Envelope ID: 926B8634-A476-4A2C-A1F1-AD31A7DA79D8

conversations about blood cancers, blood disorders, and the importance of joining the stem cell registry.

Cecilia’s journey is a testament to the impact one person can make. She’s not only keeping her mother’s memory alive – she’s helping save the lives of others.

“I want to bring happiness to people, to see smiles on their faces, as I understand the hopelessness they and their families feel upon hearing a diagnosis,” she says.

10

01 Surpassing donor registration

02 Representation matters

03 From frontline to lifeline

04 @ From grief to giving

05 Giving back through fundraising

06 DKMS UK support

05 Giving back through fundraising

Matty from Newcastle was just 25 when he received the devastating diagnosis of Hodgkin lymphoma, an aggressive blood cancer.

Six years later, thanks to a selfless donor on the DKMS stem cell register, Matty is thriving.

“It was a very tough challenge starting at 4am and finishing at 6pm. I ended up walking 50,000 steps that day! However, it was all worth it, as we raised £4,345 for DKMS, which was incredibly rewarding.”

11

Docusign Envelope ID: 926B8634-A476-4A2C-A1F1-AD31A7DA79D8

Motivated by his experience, Matty is determined to give back by fundraising to support DKMS’s lifesaving mission.

“When a group of my friends and I decided to organise a charity golf tournament, we all agreed to support DKMS through this event, as the charity had helped find my matching stem cell donor. Everyone wanted to contribute because they knew how DKMS had helped save my life.”

It costs DKMS £40 to register a potential donor to the stem cell register, meaning Matty and his friends raised enough to cover the cost of 108 potential lifesavers.

Matty’s stem cell donor gave him a second chance at life; valuable time which he is using to help other patients find their perfect match. He’s also embracing new challenges and appreciating everyday pleasures.

“Since my transplant, I’ve competed in the World Transplant Games, winning two silver medals in slalom snowboarding in Banff, Canada, and I’m gearing up to compete again next year in Dresden, Germany. Being outside has been a huge part of my healing. Even the simple things, like taking my dog to the beach every day, I feel so grateful for.”

12

01 Surpassing donor registration

02

Representation matters

03

From frontline to lifeline

04

==> picture [45 x 19] intentionally omitted <==

----- Start of picture text -----
From grief
to giving
----- End of picture text -----

05 Giving back through fundraising

06 DKMS UK support

06 DKMS UK support to India

for people of similar heritages, including in the UK where ethnic minority communities are very underrepresented on the stem cell donor register.

In 2024, DKMS UK played a vital role in strengthening India’s efforts against blood cancer and other blood disorders through marketing and outreach.

These efforts resulted in over 55,000 online and in-person registrations, with a wider, positive impact on DKMS’ goal of increasing the donor pool with more diverse HLA types.

DKMS’ global Access to Transplantation programme, offering patients in low-income countries access to treatment for blood cancers and disorders, also plays an essential role, as we see in Jasper’s story below.

Potential donors registered in India not only offer hope for their compatriots, but also worldwide

Jasper - Access to Transplantation

fly Jasper, Mercy and their mother Carol to Bangalore, India, where Jasper had a stem cell transplant at the DKMS-funded BMJHSankalp Centre.

Mirror reporter Jeremy Armstrong met Jackson in Zambia, who told him that he had lost a son to sickle cell disease and now his 11-year-old, Jasper, also had it.

After ten months of care, Jasper was back home in time for Christmas and his twelfth birthday.

Jeremy connected them with DKMS UK. We facilitated free HLA typing and Jasper’s sister Mercy was a perfect stem cell donor match. Because the potentially lifesaving procedure is unavailable in Zambia, Jeremy, The Mirror and DKMS’ Access to Transplantation programme worked together to

Jasper’s story is a powerful reminder that access to healthcare should not depend on geography and the ability to access care.

==> picture [465 x 77] intentionally omitted <==

13

Docusign Envelope ID: 926B8634-A476-4A2C-A1F1-AD31A7DA79D8

Our work in pictures

14

Docusign Envelope ID: 926B8634-A476-4A2C-A1F1-AD31A7DA79D8

DKMS Foundation: Trustee Report

Preparation of report

The company qualifies as small under section 383 of the Companies Act 2006, the strategic report required of medium and large companies under The Companies Act 2006 (Strategic Report and Director’s Report) Regulations 2013 is not required.

DKMS Foundation (referred to hereinafter as ‘DKMS UK’) is incorporated as a charitable company limited by guarantee and is a registered charity in England and Wales, and in Scotland. It is governed by its Memorandum and Articles of Association. The activities, management, finances and strategy of the Charity are overseen by a Board of Trustees, who are also the Company Directors.

DKMS UK is connected through common Trustees to DKMS Group gGmbH (‘DKMS’), and its related charities.

The Trustees who held office during the financial year and at the date of the report are set out on page 56.

A minimum of two Trustees at any one time are required by the Articles of Association. There is no maximum limit required by the Articles.At every Annual General Meeting (AGM) one-third of the Trustees retire by rotation and are eligible for re-election. There is no restriction on the term of tenure as a Trustee. Trustees do not receive remuneration for their duties.

Purpose

DKMS UK’s charitable purposes are set out in its Memorandum of Association as follows:

“The preservation and protection of good health and the relief of sickness of individuals who are suffering from any kind of blood cancer.”

The aims of DKMS UK are to:

Public benefit

DKMS UK raises awareness of blood cancers and blood disorders in the UK, including the life-changing impact of a diagnosis, in order that increasing numbers of the general public know about the need for more people to register as a potential blood stem cell donor. Increasing the number and diversity of potential blood stem cell donors is vital in increasing the life chances of blood cancer and disorder patients who need a blood stem cell transplant. At present, only 7% of the UK’s eligible population are registered as donors compared to much higher levels in some other countries.

Registering more potential blood stem cell donors means that we are able to provide more second chances at life by finding and supporting an unrelated blood stem cell donor who can and will donate their stem cells for a patient in need of a life-saving blood stem cell transplant.

Through recruiting, registering and supporting blood stem cell donors to be part of life-saving treatments, we deliver significant public benefit to patients and their families and to the National Health Service, which arranges treatment and care for those patients.

The Trustees review the aims, objectives and activities of DKMS UK each year, ensuring the Charity remains focused on its stated purpose. This report looks at what DKMS UK has achieved and the outcomes of its work in the reporting period.

The Trustees have referred to the guidance contained in the Charity Commission’s general guidance on public benefit when reviewing the Charity’s aims and objectives and in planning its future activities. In particular, the Trustees consider how planned activities will contribute to the aims and objectives that have been set.

15

Docusign Envelope ID: 926B8634-A476-4A2C-A1F1-AD31A7DA79D8

Board and management operations

The Board of Trustees meets twice a year to review DKMS UK’s work, finances and services, and to agree the strategic goals for the Charity.

Recruitment and appointment of new Trustees

Trustees are appointed on the basis of their relevant skills and experience. The ongoing Trustees are responsible for the induction of any new Trustees, which involves an awareness of a Trustee’s responsibilities, the governing document, administrative procedures, the history, approach and current business plan of DKMS UK.

The Trustees also make available a welcome pack to include copies of the previous year’s annual report and financial statements, a brief history of the charitable company and a copy of the governing document. The pack also includes a copy of the Charity Commission guidance ‘The essential Trustee: What you need to know. What you need to do.’

The Senior Leadership Team comprises:

Related parties

The only related parties are considered to be the Trustees and those connected with the Trustees, including their close family, business and other charity interests. There have been no transactions with related parties, nil reimbursement to Trustees.

While DKMS UK is connected through common Trustees to DKMS Group gGmbH (‘DKMS’), it continues to aim to recruit additional Trustees that can broaden and support its representation in the UK.

Management and organisation

Day-to-day operations of the Charity and strategy implementation is delegated to the Country Managers supported by the Senior Leadership Team (SLT). In the absence of the Country Managers, Stephan Schumacher, Trustee oversees the work of the SLT.

16

Docusign Envelope ID: 926B8634-A476-4A2C-A1F1-AD31A7DA79D8

DKMS Foundation: Trustee Report

Remuneration

In order to recruit and retain staff of the calibre it requires, DKMS UK’s pay policy is to remunerate staff at levels above the voluntary sector median rate, but below the private sector market rate. The Charity has an organisational salary structure based upon a job evaluation study and external salary benchmarking concluded in June 2023. New roles are assessed against the job evaluation criteria and placed in a corresponding grade in the structure.

Our approach to fundraising

We continue to uphold the highest standards in how we communicate with our fundraising donors and supporters and ensure that our fundraising practices meet the requirements of the recommended Codes of Practice.

We treat our donors and supporters with great respect and gratitude that befits a community of people and organisations that make our work possible.

The salary structure’s pay levels are reviewed at least annually by the Country Managers to ensure that salary scales are aligned with those for similar positions in the external market. A review of salaries normally takes place annually, and is usually implemented in January. If changes are to be made, staff are advised in writing of the amount and the date from which it takes effect. A salary review does not imply an increase and in making any pay award the review will be based on the organisation’s financial health and achievements.

With reference to the National Council of Voluntary Organisation’s 2014 inquiry into executive pay (NCVO, Report of the Inquiry into Charity Senior Executive Pay and Guidance for Trustees on Setting Remuneration), the Board of Trustees is committed to including the following information within its annual statutory report and financial statements:

Key aspects of our approach to fundraising include:

Registration with the Fundraising Regulator, which maintains the standards for charitable fundraising and ensures that fundraising is respectful, open, honest and accountable to the public. It also takes complaints about fundraising, investigates cases and adjudicates on fundraising practice.

Ensuring our fundraising approach is aligned with the Charity’s governing objectives.

We have a complaints policy, which outlines our commitment to resolving fundraising complaints as promptly and amicably as possible. It also sets out our process for handling any complaints received. As per our policy, complaints will be reported and referred to the Fundraising Regulator if a resolution with the complainant cannot be reached or if the complaint is about a breach of any aspect of the Code of Fundraising Practice.

17

Docusign Envelope ID: 926B8634-A476-4A2C-A1F1-AD31A7DA79D8

In 2024 we did not receive any complaints across the organisation. Trustees are updated on a bi-annual basis with regards to the number of complaints we have handled in the year.

We raise funds through individual giving requests (cash appeals, regular donation asks and online giving), community, challenge events, corporate and trust fundraising.

We do not carry out any telephone, face-to-face or door-to-door fundraising.

We do not use third party agencies to make fundraising requests, although we do use them for fulfilment purposes, e.g. acquisition of charity place challenge events, processing direct debits or distribution of fundraising direct mail. In such situations, legal agreements are in place. In no other circumstance do we swap or share data and we never sell data.

All fundraising activity complies with the UK General Data Protection Regulation (GDPR) and associated legislation and guidance.

Promotional goods sent out for fundraising purposes, and use of our logo on external fundraising materials, is subject to approval. Official stationery, such as our letterhead, is never sent out for external use.

Risk assessment and management

DKMS UK operates a risk assessment and management framework that reviews major risk areas on a quarterly basis.

Medical safety of donors during the blood stem cell collection process

Although the medical process and procedure for blood stem cell donation and collection is safe, well-established and regulated, there will always be some safety risks and DKMS UK acknowledges these and takes them seriously.

The risks to the safety of our donors before, during and after the donation process, as well as any risks to transplant patients from the collection of poor-quality stem cell product are managed and mitigated in the following ways:

The Country Managers and individual members of the SLT take responsibility for the day-to-day management and oversight of the above risk areas. The Trustees review the assessments and mitigating actions at their Board meetings and consider the following areas to be the major risks related to DKMS UK’s operations and activities.

18

Docusign Envelope ID: 926B8634-A476-4A2C-A1F1-AD31A7DA79D8

DKMS Foundation: Trustee Report

Data management and protection

The collection, processing, storage and security of our blood stem cell donors’ personal data and genetic information is of paramount importance and so represents a major risk in the event of mismanagement, loss or misuse of that data.

The potential damage to individual donors through a data breach, let alone the damage to DKMS UK’s and the DKMS Group’s reputation and activities in working with patients, donors, supporters and stakeholders would be catastrophic.

We manage and mitigate this risk by ensuring we have:

We manage and mitigate these risks through:

Financial risks

There are a number of areas of financial risk faced by DKMS UK:

Effective and high-quality blood stem cell donor recruitment is essential to ensuring we meet the needs of patients and transplant centres looking for a match. If we fail to ensure we recruit sufficient numbers of donors with a diverse range of backgrounds, and also with accurate and regularly updated personal health and genetic information and contact details, then we risk not being able to save the lives of more blood cancer and blood disorder patients.

These risks are managed and mitigated in the following ways:

• Ensuring pricing of products and services is set at reasonable and affordable levels, that recognise the Group’s role as a healthcare service provider with a primary objective of saving lives. Pricing levels are based on a production cost structure and also acknowledge differences in international economies, as well as the need to ensure patient treatments

are not jeopardised by costs.

19

Docusign Envelope ID: 926B8634-A476-4A2C-A1F1-AD31A7DA79D8

Logistical and supply line business continuity and resilience

Ensuring we have reliable, efficient and cost-effective methods for transporting our swab packs, blood samples and collected blood stem cells is crucial to the successful achievement of our organisational goals and objectives to save more lives, as is having a well-stocked and maintained supply line, resources and medicines. To manage and mitigate the risks of business-critical supplies and logistical arrangements we have:

UK’s economic challenges and its effects on DKMS UK business activities

The UK economy in common with almost all countries in the world experienced a sharp increase in the cost of living with inflation reaching over 11% for a short period in late 2022. The Bank of England and the UK government implemented various economic policies to prevent the inflation rate imbedding in the economy and spiralling out of control. Fall in energy prices and good economic governance has resulted in reducing UK’s inflation rate to about 2.5% by mid2024. The UK economic outlook now appears more positive and predictable. However significant part of the cost increases cannot be passed on and are therefore absorbed by the charity. The UK inflation rate remains at 3.8%.

Financial review

Going concern

The Board of Trustees of the ultimate parent company approved an arrangement to continue funding DKMS UK’s main activities to meet all its liabilities from its principal, DKMS Group gGmbH for a period not less than 12 months from the date these financial statements are approved. Accordingly, the Trustees continue to adopt a going concern basis in preparing the financial statements.

The company’s business activities in 2024 show positive results to budget and the trend is expected to continue for rest of the year with the company’s funding requirements expected to remain well within the amounts approved by the board for next three years.

The charitable company’s net current assets at 31 December 2024 were 2,410,827 (2023: £2,665,040). Further details regarding the adoption of the going concern basis can also be found in the Accounting Policies on page 30.

20

Docusign Envelope ID: 926B8634-A476-4A2C-A1F1-AD31A7DA79D8

DKMS Foundation: Trustee Report

Financial results

DKMS UK received donations totalling £4,817,209 (2023: £3,597,777) of which £3,025.173, (2023: £2,559,143) was donated funds, £1,792,036 (2023: £1,038,634) was donated services from DKMS in Germany.

The charity company’s net expenditure for the year amounted to £28,759 (2023: net income £459,791) The reduction in net income was influenced by absorption of higher costs for its charitable activities and costs of supporting and growing DKMS brand awareness in India. This is to encourage donor awareness and registration for treatment of blood cancer, Thalassemia and other blood disorders.

Reserves policy

DKMS UK’s aim is to gradually grow its unrestricted funds and achieve full financial independence. While the Charity is growing its income base and cash flow, it continues to receive funding for its main activities from its principal, DKMS Group gGmbH. The Trustees have approved for this arrangement to continue for the foreseeable future and until DKMS UK becomes financially independent to meet all its liabilities for at least 12 months. As at 31 December 2024 DKMS UK’s unrestricted funds were £2,659,153 (2023: £2,687,912).

Future developments

DKMS remains focussed on achieving steady growth in number of stem cell donations.

We are aware that our donation volume may show some reduction over next 2-3 years as we refocus on increasing our donor pool of young and preferred aged donor group.

Recruitment must remain targeted, with a particular focus on young donors and from ethnic minority communities, as those groups will further help increase our overall number of matched donors, and move us closer to levelling up access to transplantation in these communities.

Fundraising work is planned to grow significantly over the next three years to support our expansion, with important areas for future growth being community-based and volunteer-led programmes, along with an expanded corporate support programme. This support is vital to achieve our aim of finding a matching donor for every stem cell transplant patient that needs one and where required covering the costs of the transplant.

Change of trustees and directors

Dr A H Schmidt resigned as Trustee on 22nd January 2025.

Principal funding

In the period under review, DKMS UK’s significant funding comes from donations from DKMS Group in Germany. In the meantime, the charitable company continues to grow its fee income from referral of potential blood stem cell donors and management of peripheral blood stem cell or bone marrow collections and establishing a broader base of additional funding sources to grow its voluntary donation income.

The charity has also developed a fundraising strategy to raise additional funding through new voluntary donations initiatives and events.

21

Docusign Envelope ID: 926B8634-A476-4A2C-A1F1-AD31A7DA79D8

Trustees’ responsibilities statement

The Trustees (who are also directors of DKMS Foundation for the purposes of company law) are responsible for preparing the Trustees’ report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company law requires the Trustees to prepare financial statements for each financial year. Under company law the Trustees must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the charitable company and of the incoming resources and application of resources, including the income and expenditure, of the charitable company for that period.

Disclosure of information to auditors

Each of the persons who are Trustees at the time when this Trustees’ report is approved has confirmed that:

This report was approved by the Trustees and signed on their behalf by:

In preparing these financial statements, the Trustees are required to:

Bernd Weinel Trustee

Date: 7th November 2025

22

Docusign Envelope ID: 926B8634-A476-4A2C-A1F1-AD31A7DA79D8

DKMS Foundation: Independent auditors’ report to the members and trustees

Opinion

We have audited the financial statements of DKMS Foundation (the ‘charity’) for the year ended 31 December 2024 which comprise the Statement of Financial Activities, Balance Sheet, Statement of Cash Flows and notes to the financial statements, including a summary of significant accounting policies.

The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (United Kingdom Generally Accepted Accounting Practice).

In our opinion, the financial statements:

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the trustees use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the charity's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the trustees with respect to going concern are described in the relevant sections of this report.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the “Auditor’s responsibilities for the audit of the financial statements” section of our report. We are independent of the charity in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC’s Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

23

Docusign Envelope ID: 926B8634-A476-4A2C-A1F1-AD31A7DA79D8

Other information

The other information comprises the information included in the trustees’ report, other than the financial statements and our auditor’s report thereon. The trustees are responsible for the other information contained within the annual report. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

Opinions on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of the audit:

Matters on which we are required to report by exception

In light of the knowledge and understanding of the charity and its environment obtained in the course of the audit, we have not identified material misstatements in the directors’ report included within the trustees’ report.

We have nothing to report in respect of the following matters in relation to which the Companies Act 2006 and Charities Accounts (Scotland) Regulations 2006 requires us to report to you if, in our opinion:

24

Docusign Envelope ID: 926B8634-A476-4A2C-A1F1-AD31A7DA79D8

DKMS Foundation: Independent auditors’ report to the members and trustees

Responsibilities of Trustees

As explained more fully in the trustees’ responsibilities statement set out on page 22, the trustees (who are also directors of the charity for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the trustees are responsible for assessing the charity’s ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the charity or to cease operations, or have no realistic alternative but to do so.

Auditors’ responsibilities for the audit of the financial statements

We have been appointed as auditor under Section 44(1)(C) of the Charities and Trustee Investment (Scotland) Act 2005 and under the Companies Act 2006 and report in accordance with the Acts and relevant regulations made or having effect thereunder.

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor’s report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the financial statements.

The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below.

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud.

Based on our understanding of the charity and its sector, we considered that non-compliance with the following laws and regulations might have a material effect on the financial statements: employment regulation, health and safety regulation, anti-money laundering regulation.

To help us identify instances of non-compliance with these laws and regulations, and in identifying and assessing the risks of material misstatement in respect to non-compliance, our procedures included, but were not limited to:

25

Docusign Envelope ID: 926B8634-A476-4A2C-A1F1-AD31A7DA79D8

We also considered those laws and regulations that have a direct effect on the preparation of the financial statements, such as tax legislation, pension legislation, the Charities Act 2011 and the Companies Act 2006.

In addition, we evaluated the trustees’ and management’s incentives and opportunities for fraudulent manipulation of the financial statements, including the risk of management override of controls, and determined that the principal risks related to posting manual journal entries to manipulate financial performance, management bias through judgements and assumptions in significant accounting estimates, in particular in relation to accruals, income recognition (which we pinpointed to the cut-off assertion) and significant one-off or unusual transactions.

Use of the audit report

This report is made solely to the charity’s members as a body in accordance with Chapter 3 of Part 16 of the Companies Act 2006, and to the charity’s trustees, as a body, in accordance with Regulation 10 of the Charities Accounts (Scotland) Regulations 2006. Our audit work has been undertaken so that we might state to the charity’s members and trustees those matters we are required to state to them in an auditor’s report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charity, the charity’s members as a body and the charity’s trustees as a body for our audit work, for this report, or for the opinions we have formed.

Our audit procedures in relation to fraud included but were not limited to:

Nicola Wakefield (Nov 12, 2025 08:09:05 GMT)

Nicola Wakefield (Senior Statutory Auditor) for and on behalf of Forvis Mazars LLP.

Chartered Accountants and Statutory Auditor, 6 Sutton Plaza, Sutton Court Road, Sutton Surrey, SM1 4FS.

Date: 12th November 2025

26

Docusign Envelope ID: 926B8634-A476-4A2C-A1F1-AD31A7DA79D8

DKMS Foundation: Statement of financial activities

(Incorporating income and expenditure account) for the year ended 31 December 2024


for the year ended 31 December 2024
for the year ended 31 December 2024
Unrestricted funds
2024		 Total funds
2024		 Total funds
2023
Note £ £ £
Income from
Donations and legacies
2
Charitable activities
3
Total Income
Expenditure on
Raising funds
4
Charitable activities
5, 6 and 9
7, 19
Net income / (expenditure)
beforeprior year VAT
adjustmentsother recognised
gains and losses
Net income relating to prior
year VAT treatment change
12
Net income / (expenditure)
before other recognised
gains and losses
Reconciliation of funds
Total funds
brought forward
Total funds
carried forward		 4,817,209
8,079,045
12,896,254
1,317,842
12,571,825
13,889,667
-993,413
964,654
-28,759
2,687,912
2,659,153		 4,817,209
8,079,045
12,896,254
1,317,842
12,571,825
13,889,667
-993,413
964,654
-28,759
2,687,912
2,659,153		 3,597,777
8,323,916
11,921,693
1,275,335
10,186,570
11,461,905
459,791
-
459,791
2,228,121
2,687,912

All activities relate to continuing operations. The unrestricted funds above includes £227,554 of income (2023:£175,000) and £227,554 of expenditure (2023:£175,000) that is restricted to fund blood cancer treatment costs for children in Africa and India and funding for nurses education and training in the UK.

The notes on pages 30 to 49 form part of these financial statements.

27

Docusign Envelope ID: 926B8634-A476-4A2C-A1F1-AD31A7DA79D8

DKMS Foundation: Balance Sheet

As at 31 December 2024

2024 2024 2023 2023
Note £ £ £ £
Fixed assets
Tangible assets 13 248,324 22,871
Investments 14 1 1
248,326 22,872
Current assets
Inventory 15 60,688 258,696
Debtors 16 2,924,811 2,058,021
Cash at bank 22 887,731 1,932,055
and in hand
3,873,230 4,248,772
Creditors: 17 (1,462,403) (1,583,732)
amounts falling due
within one year
Net current assets 2,410,827 2,665,040
Net assets 2,659,153 2,687,912
Charity Funds
Unrestricted funds 19 2,659,153 2,687,912
Total funds 20 2,659,153 2,687,912

The company’s financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

The trustees consider that the company is entitled to exemption from the requirement to have an audit under the provisions of section 477 of the Companies Act 2006 (“the Act”) and members have not required the company to obtain an audit for the year in question in accordance with section 476 of the Act. However, an audit is required in accordance with section 144 of the Charities Act 2011.

The trustees acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of financial statements.

The financial statements were approved and authorised for issue by the trustees.

Bernd Weinel

Trustee

Date: 7th November 2025

The notes on pages 30 to 49 form part of these financial statements.

28

Docusign Envelope ID: 926B8634-A476-4A2C-A1F1-AD31A7DA79D8

DKMS Foundation: Statement of cash flows

For the year ended 31 December 2024

2024 2023
Note £ £
Cash fows from
operating activities
Net cash provided by
operating activities
21
Cash fows from
investing activities
Purchase of tangible
fxed assets
Net cash used in
investing activities
Change in cash and cash
equivalents in the year
Cash and cash equivalents
brought forward
Cash and cash equivalents
carried forward
22		 (765,684)
(278,640)
(278,640)
(1,044,324)
1,932,055
887,731		 191,963
(9,848)
(9,848)
182,115
1,749,940
1,932,055

The notes on pages 30 to 49 form part of these financial statements.

29

Docusign Envelope ID: 926B8634-A476-4A2C-A1F1-AD31A7DA79D8

DKMS Foundation: Notes to the financial statements for the year ended 31 December 2024

01. Accounting Policies

1.1 Basis of preparation of financial statements

The financial statements have been prepared in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019) - (Charities SORP (FRS 102)), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Companies Act 2006.

DKMS Foundation meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy.

The financial statements are presented in pound sterling (£).

1.2 Going concern

1.3 Company status

The charitable company is limited by guarantee. The members of the company are the trustees named on the back page. In the event of the company being wound up, the liability in respect of the guarantee is limited to £10 per member of the company.

1.4 Fund accounting

General funds are unrestricted funds which are available for use at the discretion of the trustees in furtherance of the general objectives of the company and which have not been designated for other purposes.

Restricted funds are funds which are to be used in accordance with specific restrictions imposed by donors or which have been raised by the company for particular purposes. The costs of raising and administering such funds are charged against the specific fund. The aim and use of each restricted fund is set out in the notes to the financial statements.

The trustees of the ultimate parent company review the company’s activities and 3 year business plan each year and establish and approve funding level required to enable the company to achieve its goals and meet its business commitments and liabilities

The Trustees have approved arrangement to continue funding the charitable company’s main activities from its principal, DKMS Gemeinnutzige GmbH until the company becomes financially independent to meet all its liabilities for a period not less than twelve months from the date these financial statements are approved. Accordingly, they continue to adopt going concern basis in preparing the financial statements.

30

Docusign Envelope ID: 926B8634-A476-4A2C-A1F1-AD31A7DA79D8

DKMS Foundation: Notes to the financial statements for the year ended 31 December 2024

1.5 Income

All income is recognised once the charitable company has entitlement to the income, it is probable that the income will be received and the amount of income receivable can be measured reliably. Money donation income is recognised when the income is credited into the company’s account and revenue for clinical services is recognised after services are delivered.

Donated services or facilities are recognised when the charitable company has control over the item, any conditions associated with the donated item have been met, the receipt of economic benefit from the use by the charitable company of the item is probable and that economic benefit can be measured reliably. In accordance with the Charities SORP (FRS 102). General volunteer time is not recognised. Further information about volunteer contribution is included in the trustees’ report.

On receipt, donated professional services and donated facilities are recognised on the basis of the value of the gift to the charitable company which is the amount the charitable company would have been willing to pay to obtain services or facilities of equivalent economic benefit on the open market; a corresponding amount is then recognised in expenditure in the period of receipt.

Income tax recoverable in relation to donations received under Gift Aid or deeds of covenant is recognised at the time of the donation.

1.6 Expenditure

1.7 Tangible fixed assets and depreciation

Tangible fixed assets are carried at cost, net of accumulated depreciation and any provision for impairment. Depreciation is provided at rates calculated to write off the cost of fixed assets, less their estimated residual value, over their expected useful lives on the following bases:

Expenditure is recognised once there is a legal or constructive obligation to make payment to a third party, it is probable that settlement will be required and the amount of the obligation can be measured reliably.

All expenditure is accounted for on an accruals basis. All expenses including support costs and governance costs are allocated to the applicable expenditure headings:

31

Docusign Envelope ID: 926B8634-A476-4A2C-A1F1-AD31A7DA79D8

DKMS Foundation: Notes to the financial statements for the year ended 31 December 2024

1.8 Investments

Investments are a form of basic financial instrument and are initially recognised at their transaction value. Investments in subsidiary companies are stated at cost less diminution in value.

1.9 Interest receivable

Interest on funds held on deposit is included when receivable and the amount can be measured reliably by the company; this is normally upon notification of the interest paid or payable by the Bank.

1.14 Financial instruments

The charitable company has applied Sections 11 and 12 of (FRS 102) in respect of financial instruments.

Financial assets and financial liabilities are recognised when the charitable company becomes party to the contractual provisions of the instrument. Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the charitable company after deducting all of its liabilities.

1.10 Debtors

Trade and other debtors are recognised at the settlement amount after any trade discount offered. Prepayments are valued at the amount prepaid net of any trade discounts due.

1.11 Cash at bank and in hand

Cash at bank and in hand includes cash and short term highly liquid investments with a short maturity of three months or less from the date of acquisition or opening of the deposit or similar account.

1.12 Creditors and provisions

Creditors and provisions are recognised where the charitable company has a present obligation resulting from a past event that will probably result in the transfer of funds to a third party and the amount due to settle the obligation can be measured or estimated reliably. Creditors and provisions are normally recognised at their settlement amount after allowing for any trade discounts due.

The charitable company’s policies for its major classes of financial assets and financial liabilities are set out below.

Financial assets

Basic financial assets, including trade and other debtors, cash and bank balances, related charity working capital balances, and related charity financing are initially recognised at transaction price, unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest for a similar debt instrument. Financing transactions are those in which payment is deferred beyond normal business terms or is financed at a rate of interest that is not a market rate.

Such assets are subsequently carried at amortised cost using the effective interest method, less any impairment.

1.13 Pensions

The charitable company operates a defined contribution pension scheme and the pension charge represents the amount payable by the charitable company in respect of the year.

32

Docusign Envelope ID: 926B8634-A476-4A2C-A1F1-AD31A7DA79D8

DKMS Foundation: Notes to the financial statements for the year ended 31 December 2024

Financial liabilities

Basic financial liabilities, including trade and other creditors, bank loans and loans from related charities, are initially recognised at transaction price, unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest for a similar debt instrument. Financing transactions are those in which payment is deferred beyond normal business terms or is financed at a rate of interest that is not a market rate.

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

Impairment of financial assets

Financial assets measured at cost and amortised cost are assessed at the end of each reporting period for objective evidence of impairment. If objective evidence of impairment is found, an impairment loss is recognised in the profit and loss account.

Derecognition of financial assets and financial liabilities

Financial assets are derecognised when (a) the contractual rights to the cash flows from the asset expire or are settled, or (b) substantially all the risks and rewards of the ownership of the asset are transferred to another party or (c) despite having retained some significant risks and rewards of ownership, control of the asset has been transferred to another party who has the practical ability to unilaterally sell the asset to an unrelated third party without imposing additional restrictions.

Financial liabilities are derecognised when the liability is extinguished, that is when the contractual obligation is discharged, cancelled or expires.

Critical accounting estimates and areas of judgment

Management does not consider there to be any key judgements or estimates made in the preparation of the financial statements.

For financial assets measured at cost less impairment, the impairment loss is measured as the difference between the asset’s carrying amount and the best estimate of the amount the charitable company would receive for the asset if it were to be sold at the reporting date.

For financial assets measured at amortised cost, the impairment loss is measured as the difference between the asset’s carrying amount and the present value of estimated cash flows discounted at the asset’s original effective interest rate. If the financial asset has a variable interest rate, the discount rate for measuring any impairment loss is the current effective interest rate determined under the contract.

If there is a decrease in the impairment loss arising from an event occurring after the impairment was recognised, the impairment is reversed. The reversal is such that the current carrying amount does not exceed what the carrying amount would have been had the impairment not previously been recognised. The impairment reversal is recognised in profit or loss.

33

Docusign Envelope ID: 926B8634-A476-4A2C-A1F1-AD31A7DA79D8

DKMS Foundation: Notes to the financial statements for the year ended 31 December 2024

02. Donations and legacies

Unrestricted
funds 2024		 Total funds
2024		 Total funds
2023
£ £ £
Donation income
International
donation income
Funding for donor
recruitment
activities from DKMS
Gemeinnutzige GmbH
Other income
Total donations
and legacies
Total 2023		 1,963,061
1,062,112
1,792,036
-
4,817,209
3,597,777		 1,963,061
1,062,112
1,792,036
-
4,817,209
3,597,777		 1,906,353
652,790
1,038,634
-
3,597,777

Donation income includes £227,554(2023 £175,000) collected to fund blood cancer treatment costs for children in Africa and India and funding for nurses education and training in the UK.

03. Charitable activities

Unrestricted
funds 2024		 Total funds
2024		 Total funds
2023
£ £ £
Income from
service provision
Total 2023		 8,079,045
8,323,916		 8,079,045
8,323,916		 8,323,916

In the year ended 31 December 2024 and 2023 all income related to unrestricted funds.

34

Docusign Envelope ID: 926B8634-A476-4A2C-A1F1-AD31A7DA79D8

DKMS Foundation: Notes to the financial statements for the year ended 31 December 2024

04. Raising funds

Unrestricted
funds 2024		 Total funds
2024		 Total funds
2023
£ £ £
Salaries, national
insurance and pensions
Other staff costs
and training
Premises costs
Publicity &
Awareness costs
Postage, support
and stationery
Other admin costs
Travel costs
Loss on foreign exchange
Depreciation
Total 2023		 433,322
22,689
65,546
586,347
3,396
174,340
5,995
18,495
7,712
1,317,842
1,275,335		 433,322
22,689
65,546
586,347
3,396
174,340
5,995
18,495
7,712
1,317,842
1,275,335		 398,184
29,990
43,195
600,138
1,794
170,539
6,367
17,218
7,910
1,275,335

35

Docusign Envelope ID: 926B8634-A476-4A2C-A1F1-AD31A7DA79D8

DKMS Foundation: Notes to the financial statements for the year ended 31 December 2024

05. Direct costs

Recruitment
of Donors		 Recruitment
of Donors		 Raising
Awareness		 Donor
Request
Management		 Total
2024		 Total
2023
£ £ £ £ £
Other direct costs
International donor
projects - India - Africa
Other staff costs
and training
Premises cost
Publicity cost
Loss on
foreign exchange
Postage, support
and stationery
Travel costs
Donor typing costs
Salaries, national
insurance and pensions
Depreciation
Total 2023		 168,740
1,008,727
628
70,954
77,108
17,432
199,843
32,317
1,062,112
375,377
7,269
3,020,508
2,121,295		 35,719
1,775,824
394
116,416
269.832
17,432
121,919
5,822
-
363,960
7,269
2,714,587
2,364,863		 3,643,346
-
(5,576)
125,186
12,204
41,401
143,204
19,841
-
874,526
17,263
4,871,396
4,270,456		 3,847,805
2,784,551
(4,554)
312,557
359,144
76,266
464,966
57,981
1,062,112
1,613,862
31,801
10,606,491
8,756,614		 3,313,754
2,053,219
11,506
194,271
358,734
58,255
331,409
28,322
1,038,634
1,341,748
26,762
8,756,614

Direct costs includes £227,554(2023 £175,000) collected to fund blood cancer treatment costs for children in Africa and India and funding for nurses education and training in the UK.

36

Docusign Envelope ID: 926B8634-A476-4A2C-A1F1-AD31A7DA79D8

DKMS Foundation: Notes to the financial statements for the year ended 31 December 2024

06. Support costs

Recruitment
of Donors		 Recruitment
of Donors		 Raising
Awareness		 Donor
Request
Management		 Total 2024 Total 2023
£ £ £ £ £
Legal and
professional fees
Loss on
foreign exchange
Other staff costs
and training
Premises costs
Travel costs
Other support costs
Postage, support
and stationery
Admin costs
Salaries, national
insurance and pensions
Depreciation
Total 2024
Total 2023		 23,507
7,228
29,039
24,100
2,657
110,121
560
(1,576)
228,288
3,014		 40,268
7,228
29,039
41,283
2,657
110,121
560
(1,576)
228,288
3,014
460,882
324,217		 39,855
17,166
68,968
40,859
6,311
308,300
1,331
(3,742)
542,184
7,158
1,028,391
753,798		 103,631
31,621
127,047
106,241
11,626
528,541
2,450
(6,893)
998,760
13,186
1,916,210
1,365,021		 160,697
24,965
144,394
69,379
24,834
142,938
1,122
1,243
783,979
11,470
426,938 1,365,021
287,006

In the year ended 31 December 2024 and 2023 all expenditure related to unrestricted funds.

37

Docusign Envelope ID: 926B8634-A476-4A2C-A1F1-AD31A7DA79D8

DKMS Foundation: Notes to the financial statements for the year ended 31 December 2024

07. Analysis of expenditure by expenditure type

Staff
Costs
2024		 Depreciation
2024		 Other Costs
2024		 Total
2024		 Total
2023
£ £ £ £ £
Expenditure on raising
voluntary income
Costs of raising funds
Recruitment of donors
Raising awareness
Donor request
management
Charitable activities
Expenditure on
governance
Total 2024
Total 2023		 433,322
433,322
603,665
592,248
1,416,710
2,612,622
0
3,045,944
2,523,912		 7,712
7,712
10,283
10,283
24,422
44,987
0
52,699
46,142		 876,808
876,808
2,833,499
2,572,940
4,458,654
9,865,093
49,124
10,791,024
8,891,848		 1,317,842
1,317,842
3,447,446
3,175,470
5,899,786
12,522,702
49,124
13,889,668
11,461,902		 1,275,335
1,275,335
2,408,299
2,689,081
5,024,255
10,121,635
64,932
11,461,902

Direct costs includes £227,554(2023 £175,000) collected to fund blood cancer treatment costs for children in Africa and India and funding for nurses education and training in the UK.

Expenditure on raising voluntary income has not been allocated to specific activities as all costs relate to general charitable activities.

38

Docusign Envelope ID: 926B8634-A476-4A2C-A1F1-AD31A7DA79D8

DKMS Foundation: Notes to the financial statements for the year ended 31 December 2024

08. Analysis of expenditure by activities

Activities
undertaken
directly
2024		 Support costs
2024		 Total
2024		 Total
2023
£ £ £ £
Recruitment of donors
Raising awareness
Donor request
management
Total 2024
Total 2023		 3,020,508
2,714,587
4,871,396
10,606,491
8,756,614		 426,938
460,882
1,028,391
1,916,211
1,365,021		 3,447,446
3,175,469
5,899,786
12,522,702
10,121,635		 2,408,301
2,689,080
5,024,254
10,121,635

Direct costs includes £227,554(2023 £175,000) collected to fund blood cancer treatment costs for children in Africa and India and funding for nurses education and training in the UK.

09. Governance costs

Unrestricted
funds 2024		 Total funds
2024		 Total funds
2023
£ £ £
Auditors' remuneration
Legal and professional fees
Total		 25,750
23,374
49,124		 25,750
23,374
49,124		 29,400
35,532
64,932

In the year ended 31 December 2024 and 2023 all costs of direct charitable activities related to unrestricted funds.

39

Docusign Envelope ID: 926B8634-A476-4A2C-A1F1-AD31A7DA79D8

DKMS Foundation: Notes to the financial statements for the year ended 31 December 2024

10. Net resources expended

This is stated after charging:

2024 2023
£ £
Depreciation of
tangible fxed assets
- Owned by the charity
Auditors’ remuneration - audit		 52,699
25,750		 46,142
29,400
- Non-audit services Taxation advice 31,100 26,710

During the year, no trustees received any remuneration (2023- £Nil). During the year, no trustees received any benefits in kind (2023 - £Nil).

During the year, no trustees received any reimbursement of expenses (2023 - £Nil).

40

Docusign Envelope ID: 926B8634-A476-4A2C-A1F1-AD31A7DA79D8

DKMS Foundation: Notes to the financial statements for the year ended 31 December 2024

11. Staff Costs

Staff costs were as follows:

2024 2023
£ £
Salaries
Social security costs
Pension costs
Total		 2,645,831
263,127
103,519
3,012,477		 2,197,776
218,697
80,823
2,497,296

The average monthly number of employees was: 58 (2023: 50) and the average monthly number of employees during the year expressed as follows

Full time equivalents was as follows (including part-time and fixed period temporary staff):

2024 2023
No. No.
Donor recruitment
Fundraising
Communications
Medical
Administration
Donor Service
Charity activity development
Total		 8
6
8
19
8
6
3
58		 6
6
6
17
8
6
1
50

41

Docusign Envelope ID: 926B8634-A476-4A2C-A1F1-AD31A7DA79D8

DKMS Foundation: Notes to the financial statements for the year ended 31 December 2024

The number of higher paid employees was:

2024 2023
No. No.
In the band £60,001 - £70,000
In the band £70,001 - £80,000
In the band £80,001 - £90,000
In the band £90,001 - £100,000
In the band £100,001 - £110,000
In the band £110,001 - £120,000
In the band £120,001 - £130,000
In the band £130,001 - £140,000
In the band £140,001 - £150,000
In the band £150,001 - £160,000
Total		 4
3
0
0
1
0
0
0
1
0
9		 4
1
0
0
0
1
0
0
0
0
6

The charitable company trustees were not paid or received any other benefits from employment with the charitable company in the year (2023: £Nil) neither were they reimbursed expenses during the year (2023: £Nil). No charitable company trustee received payment for professional or other services supplied to the charitable company (2023: £Nil)

The key management personnel of the charitable company are the trustees, the Chief Executive Officer,the heads of departments and team leads. There are 11 heads of department and team leads (2023: 6), nine of whom received remuneration in excess of £60,000 during the year (2023: 6). The total employee benefits of the key management personnel of the charitable company were £927,942 (2023: £626,365).

42

Docusign Envelope ID: 926B8634-A476-4A2C-A1F1-AD31A7DA79D8

DKMS Foundation: Notes to the financial statements for the year ended 31 December 2024

12. Net income relating to prior year VAT treatment change

The adjustment relates to net VAT charge following change in the charity’s VAT status from a change in Stem cell collection process in 2020. Input VAT of £656,984 is now payable and output VAT of £1,621,638 is now claimable for periods from July 2020 - December 2023

13. Tangible assets

Offce
Equipment		 Computer
Equipment		 Leasehold
Improvements		 Total
Cost £ £ £ £
At 1 January 2024
Additions
Disposals
At 31 December 2024
Accumulated
Depreciation
At 1 January 2024
Charge for the year
Release on disposal
At 31 December 2024		 69,800
123,952
(80,973)
112,779
65,887
18,623
(80,973)
3,537		 176,721
29,414
(22,176)
183,959
157,763
18,402
(21,688)
154,477		 228,855
125,274
(104,369)
249,760
228,855
15,673
(104,369)
140,159		 475,376
278,640
(207,518)
546,498
452,505
52,698
(207,030)
298,173
Net book value
At 31 December 2024 109,242 29,482 109,601 248,325
At 31 December 2023 3,913 18,958 - 22,871

43

Docusign Envelope ID: 926B8634-A476-4A2C-A1F1-AD31A7DA79D8

DKMS Foundation: Notes to the financial statements for the year ended 31 December 2024

14. Investments

Shares in GroupUndertakings Shares in GroupUndertakings
£
Costs and net book value
At 31 December 2024 and 31 December 2023 1

The company’s wholly owned subsidiary, Delete Blood Cancer UK Marketing Limited, registered at Ashburnham House, Castle Row, Horticultural Place, London W4 4JQ is a dormant company. Its net liability position at 31 December 2024. £10,245 (2023: £10,245) is represented by amounts due to parent company and is fully provided for in the accounts of the parent company.

15. Inventory

Inventory costs were as follows:

2024 2023
£ £
Materials stock
Work in progress costs
Total		 50,999
9,689
60,688		 153,757
104,939
258,696

Inventories are valued at lower of cost and net realisable value. Work in progress costs are reimbursable costs incurred for active stem cell collections awaiting to be billed.

16. Debtors

2024 2023
£ £
Due within one year
Trade debtors
Amounts owed by group undertakings
Amounts owed by related charity
Other debtors
Prepayments and accrued income
Total		 1,949,139
10,245
217,495
495,757
252,175
2,924,811		 1,505,825
10,245
332,338
8,092
201,521
2,058,021

44

Docusign Envelope ID: 926B8634-A476-4A2C-A1F1-AD31A7DA79D8

DKMS Foundation: Notes to the financial statements for the year ended 31 December 2024

17. Creditors: Amounts falling due within one year

2024 2023
£ £
Trade creditors
Amounts owed to related charity
Other creditors
Deferred revenue - UK Gala
Other taxation and social security
Accruals
Total		 431,061
6,929
109,038
223,519
80,899
610,957
1,462,403		 459,989
10,336
184,490
270,000
67,473
591,444
1,583,732

Other creditors include £223,519 (2023: £270,000) deposits received for the fundraising event scheduled to be held in May 2025.

18. Financial instruments

18. Financial instruments
2024 2023
£ £
Financial assets
Financial assets that are debt instruments
measured at amortised cost
Financial liabilities
Financial liabilities measured at amortised cost
Total		 2,672,636
(437,990)
2,234,646		 1,856,500
(470,325)
1,386,175

Financial assets measured at amortised cost include trade debtors, amounts owed by group companies, other debtors and amounts owed by related charity

Financial liabilities include trade creditors and amounts owed to a related charity.

45

Docusign Envelope ID: 926B8634-A476-4A2C-A1F1-AD31A7DA79D8

DKMS Foundation: Notes to the financial statements for the year ended 31 December 2024

19. Summary of funds

2024 2023
£ £
At 1 January
Income for year
Resource expended
Net income relating to prior
year VAT treatment change
At 31 December		 2,687,912
12,896,254
(13,889,667)
964,654
2,659,153		 2,228,121
11,921,693
(11,461,902)
-
2,687,912

20. Analysis of net assets between funds

Analysis of net assets between funds - current year:

Unrestricted funds
2024		 Total funds
2024
£ £
Tangible fxed assets
Fixed asset investments
Current assets
Creditors due within one year
Total		 248,325
1
3,873,230
(1,462,403)
2,659,153		 248,325
1
3,873,230
(1,462,403)
2,659,153

Analysis of net assets between funds - prior year:

Unrestricted funds
2023		 Total funds
2023
£ £
Tangible fxed assets
Fixed asset investments
Current assets
Creditors due within one year
Total		 22,871
1
4,248,772
(1,583,732)
2,687,912		 22,871
1
4,248,772
(1,583,732)
2,687,912

46

Docusign Envelope ID: 926B8634-A476-4A2C-A1F1-AD31A7DA79D8

DKMS Foundation: Notes to the financial statements for the year ended 31 December 2024

21. Reconciliation of net movement in funds to net cash flow from operating activities


from operating activities
2024 2023
£ £
Net income for the year
(as per Statement of Financial activities)
Adjustment for
Depreciation charges
Loss on disposal
(Increase) in debtors
Increase / (Decrease) in creditors
Decrease in inventory
Total		 (28,759)
52,698
488
(866,790)
(121,329)
198,008
(765,684)		 459,791
46,142
-
(744,872)
404,583
26,319
191,963

22. Analysis of cash and cash equivalents

2024 2023
£ £
Cash at bank and in hand
Total		 887,731
887,731		 1,932,055
1,932,055

23. Operating lease commitments

At 31 December 2024 the total of the charity’s future minimum lease payments under non-cancellable operating leases was:

2024 2023
£ £
Within 1 year
Between 2 and 5 years
Over 5 years
Total		 266,951
740,150
-
1,007,101		 266,951
1,007,101
-
1,274,052

Lease payments recognised as an expense amounted to £270,705 (2023: £255,910).

47

Docusign Envelope ID: 926B8634-A476-4A2C-A1F1-AD31A7DA79D8

DKMS Foundation: Notes to the financial statements for the year ended 31 December 2024

24. Related party transactions

The company has taken advantage of the exemption contained in FRS 102 section 33 “Related Party Disclosures” from disclosing transactions with entities which are a wholly owned part of the group. Transactions with other related parties are as follows:

Name Transaction Amount Amount Amount due from Amount due from
(relationship) / (to) related party
2024 2023 2024 2023
£ £ £ £
DKMS Donor Donated 6,250 - (395) -
Centre gGmbh services
(Common Trustees)
DKMS Donor Intercompany - 560,484 - 319,810
Centre gGmbh funding
(Common Trustees)
DKMS Group gGmbH Donated 1,062,112 1,038,634 - -
(Common Trustees) services
DKMS Group gGmbH ATT 230,000 - -
(Common Trustees)
DKMS Group gGmbH Intercompany 477,048 302,352 - (12,994)
(Common Trustees) recharges
DKMS Group gGmbH Interco funding 1,792,036 - 186,351 -
(Common Trustees)
DKMS Registry Intercompany 102,058 101,610 (5,665) (3,780)
Gemeinnutzige Gmbh service provision
DKMS USA Intercompany 29,747 10,341 (839) (942)
(Common Trustees) service provision
and recharges
DKMS USA International 50,519 7,857 - -
(Common Trustees) money donation
DKMS ASIA Intercompany 1,650,873 - - -
(India) support services
DKMS BMST Intercompany 1,011,916 2,142,741 - -
(India) support services
DKMS Foundation NPC Intercompany 35,879 50,635 14,696 12,703
(South Africa) service provision
Fundacja DKMS Intercompany 1,695 - 1,695 -
(Poland) Recharges

48

Docusign Envelope ID: 926B8634-A476-4A2C-A1F1-AD31A7DA79D8

DKMS Foundation: Notes to the financial statements for the year ended 31 December 2024

Amounts owed to related parties are unsecured, interest free and due for repayment within one year.

DKMS Group gGmbH is the Controlling company and exercises full control over the charitable company through its common Trustees who are also directors of the company. The controlling company recharges the charitable company actual or appropriately apportioned costs it incurs in providing support to the latter.

The controlling company DKMS Group gGmbH entered into a contract with DKMS Life Science Lab whereby DKMS Foundation receives typing services for no consideration from 01 January 2021.

DKMS Life Science Lab is one of the leading HLA laboratories and provides this service for all DKMS entities.

25. Post balance sheet events

No post balance sheet events.

26. Controlling party

The trustees are the immediate controlling party and DKMS Group gGmbH is the ultimate controlling party. The principal address of the ultimate parent is Kressbach 1, 72072 Tubingen, Germany.

Copies of the group financial statements are available at www.dkms.de.

49

Docusign Envelope ID: 926B8634-A476-4A2C-A1F1-AD31A7DA79D8

50

Docusign Envelope ID: 926B8634-A476-4A2C-A1F1-AD31A7DA79D8

Ways you can us support

Organise a donor registration event

Organise an event to encourage your friends, family or colleagues to register as potential stem cell donors.

Create a bespoke partnership

DKMS can provide your company with networking and marketing opportunities aligned with our purposes and shared values.

Payroll giving

Donate to DKMS through your company’s Payroll Giving Scheme if employees are paid through PAYE.

The 2K Club

Join our club of corporate supporters whose contribution goes towards helping the more than 2,000 people in the UK searching for a matching stem cell donor each year.

Sponsored activities

From local 10k runs and marathons to multi-day cycle trips, challenge yourself and get fit!

Fundraising events

Whether holding a bake sale, organising a music night or giving up a vice, every penny you raise helps in the fight against blood cancer.

Daredevil challenges

If you fancy standing on top of a plane, jumping out of one, or filling your run with obstacles, we have something for everyone.

Giving in memory

Many people choose to remember a loved one by fundraising for DKMS. We’ll help you through the process to make sure their memory lives on through our work.

==> picture [10 x 6] intentionally omitted <==

----- Start of picture text -----
51
----- End of picture text -----

Soak Sy 51

Docusign Envelope ID: 926B8634-A476-4A2C-A1F1-AD31A7DA79D8

52

Docusign Envelope ID: 926B8634-A476-4A2C-A1F1-AD31A7DA79D8

“We would like to say a huge thanks to all Charitable Trust funders and Foundations who gave us their generous and ongoing support”

53

Docusign Envelope ID: 926B8634-A476-4A2C-A1F1-AD31A7DA79D8

A huge thank you

We would like to say a huge thanks to all Charitable Trust funders and Foundations who gave us their generous and ongoing support especially:

PF Charitable

C.A. Rookes Charitable Trust B-CH 1971 Charitable Trust Beaverbrook Charitable Trust

Gallagher Insurance Neighbourly Fund

Hudson Charitable Trust Old Epsomian Lodge

The Artemis Charitable Foundation

The Clemens Neumann Nathan Charitable Trust

The Mistra Trust

54

Docusign Envelope ID: 926B8634-A476-4A2C-A1F1-AD31A7DA79D8

Trustees

Dr. E Neujahr B J Abel Bernd Weinel Dr. A H Schmidt (resigned 22nd January 2025) S Schumacher

Principal staff

Hasnein Alidina, Country Manager, Finance and Operations

Peter McCleave, Country Manager, Communications and Engagement

Registered company number

08151279

Charity registered number

110,000

Transplants for people in need

12m

Potential donors registered

24

Lifesaving stem cell donations each day*

1150056 (England & Wales)

SC046917 (Scotland)

*Global DKMS statistics as of 31 December 2024

Registered office

Ashburnham House, Castle Row, Horticultural Place London W4 4JQ

Company secretary

B J Abel

Independent auditors

Forvis Mazars LLP 6 Sutton Plaza Sutton Court Road Sutton Surrey SM1 4FS

Bankers

Barclays Bank plc 74 Shepherds Bush Green Shepherds Bush London W12 8QD

Commerzbank AG 30 Gresham Street London EC2V 7PG

DKMS is the trading name of DKMS Foundation, a company limited by guarantee registered in England and Wales (08151279) and a charity registered in England and Wales (1150056) and Scotland (SC046917).